Dr. James H. Schultz, MD

Dr. Schultz practices at Neighborhood Healthcare - Escondido Elm in Escondido, California.

Dr. Schultz's NPI, 1356376164, was assigned on July 11, 2006. Dr. Schultz graduated from David Geffen School of Medicine at UCLA in 1985. Dr. Schultz holds California license G61829.

Dr. Schultz's primary practice is Neighborhood Healthcare - Escondido Elm, at 460 Nrth Elm, Escondido, CA 92025 in San Diego County. The practice phone is (760) 737-2000.

Dr. Schultz's primary practice is Neighborhood Healthcare - Escondido Elm in Escondido, California. Dr. Schultz is also affiliated with Palomar Medical Center Downtown Escondido. The medical group on file is Vituity. Dmand AI also links Dr. Schultz to 2 more medical groups, each named with a free account. Dr. Schultz's employer is on file too: a community health center (fqhc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schultz practices, 2 sites in all. Vendor and product names are available with a free account.

Family medicine is Dr. Schultz's primary specialty in the NPI Registry, under taxonomy code 207Q00000X. Dr. Schultz is board certified in family medicine by the American Board of Family Medicine. Dmand AI has Dr. Schultz's licenses on file in 4 states: California, Hawaii, Florida and Georgia.

Dmand AI lists acute skin infection, benign or precancerous skin growths, chronic hypertension, erectile dysfunction, itchy rashes, obesity and parkinson's disease among the conditions Dr. Schultz treats.

CMS data shows 24 Medicare services from Dr. Schultz across 1 procedure code in 2022. Medicare paid $3,942 for them. Every service was in a facility, such as a hospital, rather than an office.

Across all payers, Dmand AI patient panel data puts Dr. Schultz's median patient age at 45, with 62% women.

In 2024, Dr. Schultz wrote 293 Medicare Part D claims for 48 patients. 87% of them were for generic drugs. CMS names the drug for 144 of them, across 5 drugs with 11 or more claims each, at $5,058 in total drug cost. In 2023, CMS named 422 claims across 24 drugs.

Dr. Schultz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Dr. Schultz, published from 2014 to 2024. 2017 was the busiest year, with 2. The most frequent topics are Diabetes Mellitus, Type 2, Glycated Hemoglobin and Colorectal Neoplasms. Dr. Schultz has published most often in Diabetes Care. Dr. Schultz's most frequent co-authors are Athena Philis-Tsimikas, MD, Samir Gupta, MD and Mariam Taleb, MD.

Dmand AI links Dr. Schultz to 11 clinical trials. 4 are still active or recruiting. Conditions studied include Diabetes Mellitus, Type 2, Diabetes Mellitus and Arthritis, Rheumatoid. Eli Lilly and Company sponsors the most, 6. Open Payments lists research payments to Dr. Schultz that name 8 trials.

CMS Open Payments shows 93 general payments to Dr. Schultz from 16 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 68% of the total. Eli Lilly and Company paid the most, $3,282. It also lists 26 research payments totaling $158,433 from 2018 to 2024, naming 8 clinical trials.

Dr. Schultz graduated from David Geffen School of Medicine at UCLA in 1985.

Dr. Schultz is in network with 10 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.